Novo Nordisk works alongside Healthcare Professionals (HCPs) and Healthcare Organisations (HCOs) to improve the development and delivery of life-enhancing and life-saving medicines for patients.
To ensure that patients have confidence in these relationships, the pharmaceutical industry is taking the lead on disclosing details of payments and other benefits in kind made by Novo Nordisk to HCPs and HCOs.
In-line with current ABPI requirements, Novo Nordisk submits information regarding transfers of the value made to healthcare organisations and healthcare professionals to the ABPI central disclosure platform. For further information, please visit www.disclosureuk.org.uk.
This page is intended for members of the UK public
UK/WB/0417/0016 April 2017